Effect of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status
This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status. 100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control...
Saved in:
Published in | European journal of medical research Vol. 30; no. 1; pp. 452 - 8 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
05.06.2025
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status.
100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups.
The total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3
, CD4
, and CD4
/CD8
and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment.
Freeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis. |
---|---|
AbstractList | Objectives This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status. Methods 100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups. Results The total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3.sup.+, CD4.sup.+, and CD4.sup.+/CD8.sup.+ and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment. Conclusions Freeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis. Keywords: Freeze-dried powder of lactic acid bacteria, Pediatric bacterial peritonitis, Immune function, Nutritional status This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status. 100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups. The total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3 , CD4 , and CD4 /CD8 and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment. Freeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis. This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status.OBJECTIVESThis study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status.100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups.METHODS100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups.The total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3+, CD4+, and CD4+/CD8+ and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment.RESULTSThe total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3+, CD4+, and CD4+/CD8+ and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment.Freeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis.CONCLUSIONSFreeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis. Abstract Objectives This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status. Methods 100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups. Results The total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3+, CD4+, and CD4+/CD8+ and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment. Conclusions Freeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis. This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status. 100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups. The total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3.sup.+, CD4.sup.+, and CD4.sup.+/CD8.sup.+ and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment. Freeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis. |
ArticleNumber | 452 |
Audience | Academic |
Author | Xue, Yang Zhang, YuTing |
Author_xml | – sequence: 1 givenname: Yang surname: Xue fullname: Xue, Yang – sequence: 2 givenname: YuTing surname: Zhang fullname: Zhang, YuTing |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40474200$$D View this record in MEDLINE/PubMed |
BookMark | eNptkl1r1EAUhoNUbK39A15IQBBvUucrX1dSStVCwRsF74azM2d2pySZdWZS0d_gj_ak25ZdkBAyc87zvpmTvC-LoylMWBSvOTvnvGs-JMUY4xUTNd0tF5V4VpwIptqq7eSPo731cXGW0i3RrBFN2_cvimNFPSUYOyn-XjmHJpfBlS4i_sHKRo-23IZfFuNSHsBkb0ow3pYrWmP0UOaIkEec7oVbtB5yJOixP1At-hwmn30qw1T6cZwnLN08kRntYbLlNJNm2RGeMuQ5vSqeOxgSnj08T4vvn66-XX6pbr5-vr68uKmMUl2uDLdd19O7-r7tmbLC9A6A8dY1bJmG1ZbXqq0boZhERYUGpJItKLNCp2p5WlzvfG2AW72NfoT4Wwfw-r4Q4lpDpKEH1HUNzghYIXSktLh4QGtqzloOvWTk9XHntZ1XI1pD3yTCcGB62Jn8Rq_DneaCy15KTg7vHxxi-Dljynr0yeAwwIRhTloK3siGN50k9O0OXQOdzU8ukKVZcH3RKdFzqdRypPP_UHRZHL2hGDlP9QPBuz3BBmHImxSGefk56RB8sz_s05SPeSJA7AATQ0oR3RPCmV5yq3e51ZRbfZ9bLeQ_fZDhRg |
Cites_doi | 10.1016/j.jhep.2021.07.015 10.1097/MPH.0000000000001956 10.1016/j.intimp.2022.108729 10.1097/MEG.0000000000001109 10.1097/TIN.0000000000000332 10.3949/ccjm.90a.22028 10.1007/s12602-021-09895-0 10.1097/MEG.0000000000002524 10.1097/MD.0000000000019887 10.3390/nu15051141 10.1177/0049475520905745 10.1097/IPC.0000000000000853 10.1097/MEG.0000000000001709 10.14309/ajg.0000000000002155 10.1590/S0004-28032015000300008 10.1111/ijcp.13457 |
ContentType | Journal Article |
Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. The Author(s) 2025 2025 |
Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: The Author(s) 2025 2025 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1186/s40001-025-02712-2 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2047-783X |
EndPage | 8 |
ExternalDocumentID | oai_doaj_org_article_55afc2abea8f45dea4cba7c51071a930 PMC12139331 A842913440 40474200 10_1186_s40001_025_02712_2 |
Genre | Randomized Controlled Trial Journal Article |
GroupedDBID | --- 0R~ 4.4 53G 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABUWG ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION DIK EBD EBLON EBS EMOBN F5P FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P OK1 P2P PGMZT PHGZM PHGZT PIMPY PPXIY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 UKHRP CGR CUY CVF ECM EIF NPM PMFND 7X8 5PM PJZUB PUEGO |
ID | FETCH-LOGICAL-c448t-c1d889bac997904d2c9faa017f60ffec05d1547562403e4ec06a3437a4cbef453 |
IEDL.DBID | DOA |
ISSN | 2047-783X 0949-2321 |
IngestDate | Wed Aug 27 01:29:07 EDT 2025 Thu Aug 21 18:25:31 EDT 2025 Fri Jul 11 17:09:31 EDT 2025 Tue Jun 17 21:55:27 EDT 2025 Tue Jun 10 03:43:12 EDT 2025 Tue Jun 10 02:10:33 EDT 2025 Thu Jun 19 02:16:00 EDT 2025 Thu Jul 17 06:05:14 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Freeze-dried powder of lactic acid bacteria Pediatric bacterial peritonitis Immune function Nutritional status |
Language | English |
License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c448t-c1d889bac997904d2c9faa017f60ffec05d1547562403e4ec06a3437a4cbef453 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
OpenAccessLink | https://doaj.org/article/55afc2abea8f45dea4cba7c51071a930 |
PMID | 40474200 |
PQID | 3216361683 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_55afc2abea8f45dea4cba7c51071a930 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12139331 proquest_miscellaneous_3216361683 gale_infotracmisc_A842913440 gale_infotracacademiconefile_A842913440 gale_healthsolutions_A842913440 pubmed_primary_40474200 crossref_primary_10_1186_s40001_025_02712_2 |
PublicationCentury | 2000 |
PublicationDate | 2025-06-05 |
PublicationDateYYYYMMDD | 2025-06-05 |
PublicationDate_xml | – month: 06 year: 2025 text: 2025-06-05 day: 05 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | European journal of medical research |
PublicationTitleAlternate | Eur J Med Res |
PublicationYear | 2025 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | RE Popoiag (2712_CR6) 2021; 59 R Kullar (2712_CR8) 2020; 28 J Reyna-Figueroa (2712_CR16) 2021; 43 N Ubhi (2712_CR15) 2023; 35 M Griemsmann (2712_CR5) 2022; 76 CH Wang (2712_CR11) 2020; 99 N Honar (2712_CR7) 2015; 52 A Abdel-Razik (2712_CR13) 2018; 30 SSA Souza (2712_CR17) 2021; 2 S Khan (2712_CR1) 2023; 90 H Mittal (2712_CR4) 2020; 50 L Dong (2712_CR12) 2019; 8 L Fadin (2712_CR9) 2023 L Yang (2712_CR2) 2022; 108 P Termsinsuk (2712_CR10) 2020; 74 M Avadhanam (2712_CR14) 2023; 118 J Musoke (2712_CR20) 2020; 35 Z Chen (2712_CR19) 2023; 15 M Dibas (2712_CR3) 2020; 32 D Son (2712_CR18) 2023; 15 P Zito (2712_CR21) 2022; 2 |
References_xml | – volume: 76 start-page: 230 issue: 1 year: 2022 ident: 2712_CR5 publication-title: J Hepatol doi: 10.1016/j.jhep.2021.07.015 – volume: 43 start-page: e457 issue: 4 year: 2021 ident: 2712_CR16 publication-title: J Pediatr Hematol Oncol doi: 10.1097/MPH.0000000000001956 – volume: 8 start-page: 4 year: 2019 ident: 2712_CR12 publication-title: Clin Med – volume: 108 year: 2022 ident: 2712_CR2 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2022.108729 – volume: 30 start-page: 779 issue: 7 year: 2018 ident: 2712_CR13 publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0000000000001109 – year: 2023 ident: 2712_CR9 publication-title: Topics Clin Nutr doi: 10.1097/TIN.0000000000000332 – volume: 2 start-page: 70 year: 2022 ident: 2712_CR21 publication-title: J Investig Med – volume: 90 start-page: 209 issue: 4 year: 2023 ident: 2712_CR1 publication-title: Cleve Clin J Med doi: 10.3949/ccjm.90a.22028 – volume: 15 start-page: 821 issue: 4 year: 2023 ident: 2712_CR19 publication-title: Probiotics Antimicrob Proteins doi: 10.1007/s12602-021-09895-0 – volume: 35 start-page: 384 issue: 4 year: 2023 ident: 2712_CR15 publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0000000000002524 – volume: 59 start-page: 345 issue: 4 year: 2021 ident: 2712_CR6 publication-title: Rom J Intern Med – volume: 99 issue: 21 year: 2020 ident: 2712_CR11 publication-title: Medicine doi: 10.1097/MD.0000000000019887 – volume: 15 start-page: 1141 issue: 5 year: 2023 ident: 2712_CR18 publication-title: Nutrients doi: 10.3390/nu15051141 – volume: 50 start-page: 138 issue: 2 year: 2020 ident: 2712_CR4 publication-title: Trop Doct doi: 10.1177/0049475520905745 – volume: 28 start-page: 123 issue: 3 year: 2020 ident: 2712_CR8 publication-title: Infect Dis Clin Pract doi: 10.1097/IPC.0000000000000853 – volume: 32 start-page: 1075 issue: 9 year: 2020 ident: 2712_CR3 publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0000000000001709 – volume: 118 start-page: 613 issue: 4 year: 2023 ident: 2712_CR14 publication-title: Am J Gastroenterol doi: 10.14309/ajg.0000000000002155 – volume: 2 start-page: 10 year: 2021 ident: 2712_CR17 publication-title: Current Dev Nutr – volume: 35 start-page: 104 issue: 1 year: 2020 ident: 2712_CR20 publication-title: S Afr J Infect Dis – volume: 52 start-page: 195 issue: 3 year: 2015 ident: 2712_CR7 publication-title: Arq Gastroenterol doi: 10.1590/S0004-28032015000300008 – volume: 74 issue: 3 year: 2020 ident: 2712_CR10 publication-title: Int J Clin Pract doi: 10.1111/ijcp.13457 |
SSID | ssj0000626799 |
Score | 2.38797 |
Snippet | This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and... Objectives This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune... Abstract Objectives This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 452 |
SubjectTerms | Bacteria Bacterial Infections - immunology Bacterial Infections - therapy Care and treatment Child Child, Preschool Dysbiosis Female Freeze Drying Freeze-dried powder of lactic acid bacteria Gastrointestinal Microbiome Health aspects Humans Immune function Infant Lactobacillales Male Microbiota (Symbiotic organisms) Nutritional Status Pediatric bacterial peritonitis Pediatrics Peritonitis Peritonitis - immunology Peritonitis - microbiology Peritonitis - therapy Powders Probiotics - administration & dosage Probiotics - therapeutic use Treatment Outcome |
Title | Effect of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status |
URI | https://www.ncbi.nlm.nih.gov/pubmed/40474200 https://www.proquest.com/docview/3216361683 https://pubmed.ncbi.nlm.nih.gov/PMC12139331 https://doaj.org/article/55afc2abea8f45dea4cba7c51071a930 |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtCqWX0nfcplsVCj0UEVuSJfm4KQlhIaG0DexNyJZMF4K97INCfkN-dGfkB2t66KUngzQYS9-MZgbPfCLkU55zFTKnGYTihknpOXOyTFld-0wHbkIZe2GurtXljVws8-XBVV9YE9bRA3cbd5rnrq64K4Mztcx9cLIqna5AlXTmChGzdfB5B8lUdwZzpYti6JIx6nQr01g9xLEhWWec8YknioT9fx_LB35pWjN54IQunpGnffRI591XPycPQvOCPL7q_4-_JPcdGTFta1pvQrgLzEMq7Om6_e3DBodvY1MUddXK07JjanZ0rDZHifVwecc4f0uRDnmH1r_a0rahK2wqCRR9IuJKXeNpM9D6gzh2Ke23r8jNxfnPr5esv2-BVZCk7ViVeWMKeHdR6CIF2Kqidg5MtlYpfn2aewi4NERMMhVBwoByQgqNkAQAR7wmR03bhGNCIc5wSJUnU1lK56VzuZJZLXlQHrUjIV-GvbfrjlbDxnTEKNshZQEpG5GyPCFnCM8oiZTYcQAUxfaKYv-lKAn5gODarr90NGw7N-CSMyElSHyOEmjagHHl-g4FWBKSZE0kTyaSYJLVZPrjoEAWp7COrQntfmsFh_hXZcqIhLzpFGpcFeyVlnBoJcRMVG2y7OlMs_oVGcGRl68QInv7PzbqHXnCo5koluYn5Gi32Yf3EHntyhl5qJd6Rh7N54sfC3ienV9_-z6LpvcH-vQyJw |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+freeze-dried+powder+of+lactic+acid+bacteria+treatment+of+pediatric+bacterial+peritonitis+on+immune+function+and+nutritional+status&rft.jtitle=European+journal+of+medical+research&rft.au=Xue%2C+Yang&rft.au=Zhang%2C+YuTing&rft.date=2025-06-05&rft.issn=2047-783X&rft.eissn=2047-783X&rft.volume=30&rft.issue=1&rft_id=info:doi/10.1186%2Fs40001-025-02712-2&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s40001_025_02712_2 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-783X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-783X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-783X&client=summon |